NIBRT, Valitacell Aim to Validate New Analytical Technology
The partnership, co-funded by Enterprise Ireland, will develop technologies for monitoring the quality of biopharma processes.
In a partnership with biotechnology firm Valitacell, formed in early November 2018, the National Institute of Bioprocessing Research and Training (NIBRT) aims to validate a new analytical technology developed by Valitacell known as ChemStress, which can accelerate the development and manufacture of biopharmaceutical therapies.
The collaboration, which also involves a number of large global biopharmaceutical companies, will demonstrate how Valitacell’s ChemStress can be used for quality control in cell culture media analysis. Jonathan Bones, principal investigator, NIBRT Characterization and Comparability Laboratory, will lead the project, along with Valitacell’s product manager, Karen Coss.
Valitacell technology enables companies to ensure that the media added to cells meets the quality standards that the companies have set for themselves, through smart analytics.
“We are delighted to be working with Prof. Jonathan Bones and his team. Having access to outstanding researchers and facilities at NIBRT will enable us to accelerate the development of our technology and help in our goal of bringing life-saving medicines to patients more quickly and at lower cost,” said Terry McWade, Valitacell’s CEO, in a company press release.
“NIBRT are delighted to engage with Valitacell on this exciting project. Valitacell are developing innovative technologies for monitoring the quality and behavior of complex biomanufacturing processes. Our analytical platforms strongly complement Valitacell’s ChemStress technology, and we share a common vision to ensure more efficient manufacturing of these key biological medicines,” said Bones in the press release.
The project is an Innovation Partnership co-funded by Enterprise Ireland, the European Regional Development Fund (ERDF) and the European Union. The EUR 206,283 (US$ 233,659) award will run over 18 months. The project began in November 2018.
Source: NIBRT
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
